PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
22.06%
Growth of 22.06% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
3.79%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.06%. Jim Chanos would check for structural cost disadvantages.
127.38%
Growth of 127.38% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
86.29%
Margin expansion while Drug Manufacturers - Specialty & Generic median declines. Peter Lynch would examine competitive advantages.
271.70%
R&D change of 271.70% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
19.72%
G&A change of 19.72% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
21.75%
Marketing expense change of 21.75% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-264.15%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
37.01%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.33%. Jim Chanos would check for waste.
12.96%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.90%. Jim Chanos would check for waste.
161.68%
Interest expense change of 161.68% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-3.39%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency.
113.41%
EBITDA growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
1752.23%
EBITDA margin growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
38.32%
Operating income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
49.46%
Operating margin growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
-674.13%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
60.13%
Pre-tax income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
67.33%
Pre-tax margin growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
-862.35%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
65.75%
Net income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
71.94%
Net margin growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
66.67%
EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
66.67%
Diluted EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
5.20%
Share count change of 5.20% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
5.20%
Diluted share change of 5.20% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.